- Factor advances next-generation allogeneic and in vivo CAR-T cell therapy programs
- Presentations will include latest data from Factor’s IL12-expressing iMacrophages for treating solid tumors (FACT-112), as well as recent advances in Factor’s RNA-based cell reprogramming technologies
- Factor to reveal two novel iPSC-derived mesenchymal stem cell (iMSC) programs: Hypoimmune iMSCs for muscular dystrophy and HTRA1-expressing iMSCs for neurodegenerative disorders
How Induced Pluripotent Stem Cells (iPSCs) Are Changing The World As We Know It
Since their introduction in 2006, iPSCs (or induced pluripotent stem cells) have changed the way we research and treat diseases. In large part, this is thanks to bypassing the ethical concerns associated with embryonic stem cells.
So, why exactly is everyone talking about iPSC applications and their uses within medicine?
If you’re interested in the answer, we’ve made this guide to highlight the ways these stem cells are impacting a wide variety of industries. Let’s get started. [Read more…]
Pluristyx and Qkine Announce a Reciprocal Distribution Agreement in Support of Optimized Growth Factor Differentiation of Induced Pluripotent Stem Cell (iPSC)
SEATTLE, WA and CAMBRIDGE, UK — Pluristyx, a leading provider of clinical-grade induced pluripotent stem cell (iPSC) solutions, and Qkine, a pioneer in the manufacture of high-purity, animal-free growth factors and cytokines, today announced a distribution agreement to support streamlined and efficient R&D and manufacturing of differentiated cells and tissues from iPSC. This collaboration will provide researchers, product manufacturers, and therapeutic developers with a streamlined, high-performance workflow, pre-qualified to deliver reliable differentiation of iPSCs into product cells and tissues. [Read more…]
Cartherics and Catalent Expand Partnership, Securing Clinical-Grade iPSC Line for Next-Generation CAR-NK Therapies
MELBOURNE, Australia & TAMPA, FL – Cartherics Pty Ltd, a biotech company developing off‑the‑shelf immune cell therapies for high‑impact women’s diseases, including ovarian cancer and endometriosis, and Catalent, Inc., the leader in enabling the development and supply of better treatments for patients worldwide, has announced an enhanced partnership.
The companies have signed an amended commercial license agreement enabling the use of a Catalent cGMP‑compliant induced pluripotent stem cells (iPSC) line for the manufacture and commercialization of Cartherics’ iPSC-derived Chimeric Antigen Receptor Natural Killer (CAR-NK) cell therapies. The agreement supports Cartherics’ mission to develop immune cell therapy products for the treatment of cancer and endometriosis. [Read more…]
South Korean-based “iPS Bio” Establishes Japanese Subsidiary, Deepening Ties to Japan’s iPSC Ecosystem
A South Korea–based regenerative medicine company, iPS Bio, Inc., is accelerating its international footprint with the establishment of a new Japanese subsidiary in Yokohama, Kanagawa Prefecture. The move reflects a broader trend of cross-border collaboration in the induced pluripotent stem cell (iPSC) sector, particularly between leading innovation hubs in East Asia. [Read more…]
- « Previous Page
- 1
- 2
- 3
- 4
- …
- 79
- Next Page »